Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

U-Ploid, a venture-backed biotechnology company developing next-generation fertility therapeutics, is pleased to announce the appointment of Professor Alison Campbell to its Advisory Board. In this key role, Professor Campbell will provide strategic guidance on company research programmes, working closely with the U-Ploid team to drive innovation in fertility treatments.

Professor Alison Campbell

 "We are honoured to welcome Professor Alison Campbell to our Advisory Board,” said Dr. Jordan Abdi, Co-Founder & CEO of U-Ploid Biotechnologies. "Professor Campbell's expertise in reproductive biology and her proven track record in innovation will be invaluable to U-Ploid as we work to translate cutting-edge science into effective and safe fertility treatments."

 

As Chief Scientific Officer at Care Fertility, Professor Campbell oversees 19 IVF laboratories across the UK, Ireland, Spain, and the US, and is responsible for over 12,000 IVF cycles annually with a team of more than 150 scientists. As a Consultant Embryologist and Fellow of the Royal College of Pathologists, Professor Campbell brings a wealth of expertise to the field of Embryology. Her contributions include a substantial body of published work, reflecting her commitment to reproductive medicine, having authored over 150 publications, chapters, and white papers on embryo selection, laboratory best practices, cryopreservation, and time-lapse imaging.

 

"I am excited to join U-Ploid's Advisory Board and contribute my knowledge to advancing innovative solutions to address the challenges of age-related infertility," said Professor Campbell. "U-Ploid's mission to improve access to fertility care and expand the window of reproductive opportunity deeply resonates with me, and I am eager to collaborate with the team to bring these important therapies to market."

 

As a member of the Advisory Board, Professor Campbell will work closely with U-Ploid’s leadership team and scientific advisors to shape clinical strategy, oversee study designs, and ensure the highest standards of patient safety and clinical excellence.

 

About U-Ploid Biotechnologies

U-Ploid is a biotechnology company developing next-generation fertility therapeutics to address the global challenge of age-related infertility. Co-founded by Jordan Abdi, Chloe Charalambous, and Alexandre Webster, U-Ploid is pioneering innovative solutions to improve IVF outcomes and expand the window of reproductive opportunity. The company's technology is designed to increase the quality of older eggs, restoring their potential to support healthy pregnancies. U-Ploid is committed to improving access to fertility care and envisions a future where anyone who wants to start a family, can. For more information, go to u-ploid.com or follow us on LinkedIn.

 

Press and Investor Contact

press@u-ploid.com

 

View the original press release